Founded in 2008, the firm has over $450 million in capital under management with a mission to bring bench-to-bedside innovations to market to solve unmet medical needs for the benefit of patients worldwide. SeQure Dx was founded on exclusive licensure of GUIDE-seq, ONE-seq and related assay technologies for detection of off-target gene-editing events. ”Nancy Hong, PhD, managing director at RiverVest Venture Partners said: “RiverVest is thrilled to participate in this transformative technology arena. SeQure Dx is uniquely positioned to aid gene-editing innovators in providing safe patient access to novel treatments, and we are pleased to support SeQure Dx through this accelerated growth period.”Carl Berke, PhD, a partner at Mass General Brigham Ventures, said, “Mass General Brigham Ventures has the privilege of supporting the development of this important contribution to the future of cell and gene therapy through the dedicated efforts of SeQure Dx.